327026-20-0Relevant articles and documents
Isoniazide derivative, homogeneous enzyme immunoassay reagent and preparation method
-
Paragraph 0025-0028, (2020/11/12)
The invention discloses an isoniazid derivative, a detection reagent and a preparation method, and relates to the technical field of biological detection. An isoniazid immunogen prepared from the isoniazid derivative has high immunogenicity, and an obtained antibody has strong specificity and high titer; an isoniazid enzyme-labeled conjugate in a homogeneous enzyme immunoassay reagent prepared from the derivative is connected with recombinant glucose-6-phosphate dehydrogenase modified by gene engineering; the detection sensitivity is remarkably improved, a sample with the concentration as lowas 5 ng/ml or below can be effectively detected, the specificity is high, and cross reaction with 62 common drugs is avoided; the homogeneous enzyme immunoassay reagent can realize high-throughput andrapid detection of isoniazid content on a full-automatic biochemical analyzer, and is stable in detection result, high in accuracy, simple in detection method and easy to realize, popularize and use.
Dual-action inhibitors of HIF prolyl hydroxylases that induce binding of a second iron ion
Yeoh, Kar Kheng,Chan, Mun Chiang,Thalhammer, Armin,Demetriades, Marina,Chowdhury, Rasheduzzaman,Tian, Ya-Min,Stolze, Ineke,McNeill, Luke A.,Lee, Myung Kyu,Woon, Esther C. Y.,MacKeen, Mukram M.,Kawamura, Akane,Ratcliffe, Peter J.,Mecinovi?, Jasmin,Schofield, Christopher J.
supporting information, p. 732 - 745 (2013/02/26)
Inhibition of the hypoxia-inducible factor (HIF) prolyl hydroxylases (PHD or EGLN enzymes) is of interest for the treatment of anemia and ischemia-related diseases. Most PHD inhibitors work by binding to the single ferrous ion and competing with 2-oxoglutarate (2OG) co-substrate for binding at the PHD active site. Non-specific iron chelators also inhibit the PHDs, both in vitro and in cells. We report the identification of dual action PHD inhibitors, which bind to the active site iron and also induce the binding of a second iron ion at the active site. Following analysis of small-molecule iron complexes and application of non-denaturing protein mass spectrometry to assess PHD2·iron· inhibitor stoichiometry, selected diacylhydrazines were identified as PHD2 inhibitors that induce the binding of a second iron ion. Some compounds were shown to inhibit the HIF hydroxylases in human hepatoma and renal carcinoma cell lines. The Royal Society of Chemistry 2013.